Affinity Asset Advisors, LLC Achilles Therapeutics PLC Transaction History

Affinity Asset Advisors, LLC

  • $579 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022
SELL
$4.22 - $8.86 $422,000 - $886,000
-100,000 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$5.81 - $9.93 $116,199 - $198,600
20,000 Added 25.0%
100,000 $779,000
Q2 2021

Aug 13, 2021
BUY
$9.79 - $17.86 $538,450 - $982,300
55,000 Added 220.0%
80,000 $783,000
Q1 2021

May 14, 2021
BUY
$16.55 - $16.55 $413,750 - $413,750
25,000 New
25,000 $414,000

Others Institutions Holding ACHL

# of Institutions
24
Shares Held
24.3M
Call Options Held
0
Put Options Held
0
View Full List

About Achilles Therapeutics plc

ACHL Quotes by TradingView
  • Ticker ACHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,774,000
  • Market Cap $47.3M
  • Description
  • Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...
More about ACHL
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email